Ashraf Elshafei, MD
Psychiatry · New York, NYNPI 1083816755
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.8% of the total across 466 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 21.9% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 466 payments — averaging $17.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Otsuka America Pharmaceutical, Inc.$1K
- Sunovion Pharmaceuticals Inc.$1K
- AbbVie$889
- Teva Pharmaceuticals USA, Inc.$873
- Lundbeck LLC$763
- plus $1K from 15 others
What the payments were for
- Food & beverage$7,78897%
- Education$2553%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 74 | $1,765 |
| Otsuka America Pharmaceutical, Inc. | 76 | $1,297 |
| Sunovion Pharmaceuticals Inc. | 78 | $1,144 |
| AbbVie(2 entities) | 54 | $889 |
| Teva Pharmaceuticals USA, Inc. | 45 | $873 |
| Lundbeck LLC | 67 | $763 |
| Vanda Pharmaceuticals Inc. | 12 | $241 |
| Neos Therapeutics, LP | 13 | $223 |
| E.r. Squibb & Sons, L.L.C. | 8 | $219 |
| Shire North American Group Inc | 17 | $189 |
| Supernus Pharmaceuticals, Inc. | 5 | $105 |
| Corium, LLC | 4 | $95 |
| OWP Pharmaceuticals, Inc. | 3 | $50 |
| Tris Pharma Inc | 2 | $40 |
| Alkermes, Inc. | 2 | $34 |
| Indivior Inc. | 1 | $25 |
| Johnson & Johnson | 1 | $24 |
| Neuronetics, Inc. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Bausch Health US, LLC | 1 | $16 |
| GSK | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$125
How this compares
$8,043 in reported general payments places this provider in the 90th percentile of 3,713 psychiatry providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 31 | $68,863 |
| CaplytaLumateperone Tosylate | 40 | $65,978 |
| Abilify MaintenaAripiprazole | 18 | $43,721 |
| LatudaLurasidone Hcl | 24 | $33,399 |
| Nurtec OdtRimegepant Sulfate | 11 | $32,437 |
| Aripiprazole OdtAripiprazole | 60 | $31,575 |
| OzempicSemaglutide | 31 | $29,462 |
| VraylarCariprazine Hcl | 16 | $29,194 |
| Lurasidone Hcl | 93 | $23,903 |
| TrintellixVortioxetine Hydrobromide | 43 | $19,822 |
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 20 | $15,325 |
| TrulancePlecanatide | 19 | $10,083 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 12 | $9,756 |
| Bupropion XlBupropion Hcl | 534 | $8,392 |
| Lamotrigine ErLamotrigine | 47 | $6,807 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $1,297 | $112,58349 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,765 | $65,97840 claims |
| Sunovion Pharmaceuticals Inc.Latuda | $1,144 | $33,39924 claims |
| AbbVieVraylar | $889 | $29,19416 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $17 | $19,82243 claims |
| Indivior Inc.Suboxone | $25 | $9,75612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,713 psychiatry providers in New York.
Other psychiatry in New York
- Manish ZinzuvadiaNew York$1.3M
- Jianping ChenNew York$1.2M
- Ulla Kristina LaaksoNew York$890K
- Kerry SulkowiczNew York$435K
- Ralph AquilaNew York$143K
- Daniel KarlinNew York$101K
- David StraussNew York$95K
- Anissa Abi-DarghamNew York$94K
- Robin McGarryNew York$69K
- Nicole AllenNew York$63K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.